APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

PARP (Poly ADP-Ribose Polymerase) Inhibitor

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.

In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.

Selected research

Market Analysis & Forecast

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Analysis and Forecast 2026-2032

Report ID 174022500221 December 2025191 pages

Choose your research edition.

Industry ResearchPARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.

In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.

Read the full market overview

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%.

North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent.

In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.

This report presents an overview of global market for PARP (Poly ADP-Ribose Polymerase) Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for PARP (Poly ADP-Ribose Polymerase) Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the PARP (Poly ADP-Ribose Polymerase) Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for PARP (Poly ADP-Ribose Polymerase) Inhibitor sales, projected growth trends, production technology, application and end-user industry.

PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Company

AstraZeneca

Tesaro

Merck & Co

Clovis Oncology

Pfizer

GSK

Zai Lab

PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Type

Lynparza

Zejula

Rubraca

Talzenna

Other

PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Application

Ovarian Cancer

Breast Cancer

Other

PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PARP (Poly ADP-Ribose Polymerase) Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PARP (Poly ADP-Ribose Polymerase) Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of PARP (Poly ADP-Ribose Polymerase) Inhibitor in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PARP (Poly ADP-Ribose Polymerase) Inhibitor sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Lynparza Major Manufacturers Table 3. Zejula Major Manufacturers Table 4. Rubraca Major Manufacturers Table 5. Talzenna Major Manufacturers Table 6. Other Major Manufacturers Table 7. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Ovarian Cancer Major Manufacturers Table 9. Breast Cancer Major Manufacturers Table 10. Other Major Manufacturers Table 11. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends Table 12. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Drivers Table 13. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Opportunities and Challenges Table 14. PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Restraints Table 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 18. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2021-2026) Table 19. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2027-2032) Table 20. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 21. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2021-2026) & (k units) Table 22. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2027-2032) & (k units) Table 23. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2021-2026) Table 24. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2027-2032) Table 25. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 27. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturers (2021-2026) Table 29. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price (USD/unit) of Manufacturers (2021-2026) Table 30. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers, Product Type & Application Table 33. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 38. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 39. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2021-2026) Table 40. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2027-2032) Table 41. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type 2021 VS 2025 VS 2032 (k units) Table 42. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2026) & (k units) Table 43. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2027-2032) & (k units) Table 44. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2021-2026) Table 45. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2027-2032) Table 46. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2021-2026) & (USD/unit) Table 47. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2027-2032) & (USD/unit) Table 48. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 50. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 51. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2021-2026) Table 52. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2027-2032) Table 53. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application 2021 VS 2025 VS 2032 (k units) Table 54. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2026) & (k units) Table 55. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2027-2032) & (k units) Table 56. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2021-2026) Table 57. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2027-2032) Table 58. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2021-2026) & (USD/unit) Table 59. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2027-2032) & (USD/unit) Table 60. AstraZeneca Company Information Table 61. AstraZeneca Business Overview Table 62. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 63. AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 64. AstraZeneca Recent Development Table 65. Tesaro Company Information Table 66. Tesaro Business Overview Table 67. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 68. Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 69. Tesaro Recent Development Table 70. Merck & Co Company Information Table 71. Merck & Co Business Overview Table 72. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 73. Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 74. Merck & Co Recent Development Table 75. Clovis Oncology Company Information Table 76. Clovis Oncology Business Overview Table 77. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 78. Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 79. Clovis Oncology Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 83. Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 84. Pfizer Recent Development Table 85. GSK Company Information Table 86. GSK Business Overview Table 87. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 89. GSK Recent Development Table 90. Zai Lab Company Information Table 91. Zai Lab Business Overview Table 92. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio Table 94. Zai Lab Recent Development Table 95. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 96. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 97. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2026) & (k units) Table 98. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2027-2032) & (k units) Table 99. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Type (2021-2026) & (USD/unit) Table 100. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Type (2027-2032) & (USD/unit) Table 101. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 102. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 103. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2026) & (k units) Table 104. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2027-2032) & (k units) Table 105. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Application (2021-2026) & (USD/unit) Table 106. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Application (2027-2032) & (USD/unit) Table 107. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 109. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 110. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 111. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2026) & (k units) Table 112. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2027-2032) & (k units) Table 113. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Country (2021-2026) & (USD/unit) Table 114. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Country (2027-2032) & (USD/unit) Table 115. United States PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 116. Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 117. Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 118. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 119. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 120. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2026) & (k units) Table 121. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2027-2032) & (k units) Table 122. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Type (2021-2026) & (USD/unit) Table 123. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Type (2027-2032) & (USD/unit) Table 124. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 125. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 126. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2026) & (k units) Table 127. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2027-2032) & (k units) Table 128. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Application (2021-2026) & (USD/unit) Table 129. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Application (2027-2032) & (USD/unit) Table 130. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 132. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 133. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 134. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2026) & (k units) Table 135. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2027-2032) & (k units) Table 136. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Country (2021-2026) & (USD/unit) Table 137. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Country (2027-2032) & (USD/unit) Table 138. Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 139. France PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 140. U.K. PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 141. Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 142. Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 143. Spain PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 144. Netherlands PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 145. Switzerland PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 146. Sweden PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 147. Poland PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 148. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 149. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 150. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2026) & (k units) Table 151. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2027-2032) & (k units) Table 152. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Type (2021-2026) & (USD/unit) Table 153. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Type (2027-2032) & (USD/unit) Table 154. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 155. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 156. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2026) & (k units) Table 157. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2027-2032) & (k units) Table 158. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Application (2021-2026) & (USD/unit) Table 159. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Application (2027-2032) & (USD/unit) Table 160. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 161. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 162. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2026) & (k units) Table 163. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2027-2032) & (k units) Table 164. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Type (2021-2026) & (USD/unit) Table 165. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Type (2027-2032) & (USD/unit) Table 166. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 167. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 168. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2026) & (k units) Table 169. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2027-2032) & (k units) Table 170. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Application (2021-2026) & (USD/unit) Table 171. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Application (2027-2032) & (USD/unit) Table 172. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 173. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 174. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 175. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 176. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2026) & (k units) Table 177. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2027-2032) & (k units) Table 178. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Country (2021-2026) & (USD/unit) Table 179. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Country (2027-2032) & (USD/unit) Table 180. Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 181. South Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 182. India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 183. Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 184. Taiwan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 185. Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 186. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 187. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 188. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2026) & (k units) Table 189. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2027-2032) & (k units) Table 190. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Type (2021-2026) & (USD/unit) Table 191. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Type (2027-2032) & (USD/unit) Table 192. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 193. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 194. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2026) & (k units) Table 195. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2027-2032) & (k units) Table 196. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Application (2021-2026) & (USD/unit) Table 197. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Application (2027-2032) & (USD/unit) Table 198. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 199. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 200. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 201. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 202. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021-2026) & (k units) Table 203. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2027-2032) & (k units) Table 204. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Country (2021-2026) & (USD/unit) Table 205. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Country (2027-2032) & (USD/unit) Table 206. Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 207. Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 208. Chile PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 209. Colombia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 210. Peru PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 211. Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 212. Israel PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 213. UAE PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 214. Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 215. Iran PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 216. Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Table 217. Key Raw Materials Table 218. Raw Materials Key Suppliers Table 219. PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors List Table 220. PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers List Table 221. Research Programs/Design for This Report Table 222. Authors List of This Report Table 223. Secondary Sources Table 224. Primary Sources List of Figures Figure 1. PARP (Poly ADP-Ribose Polymerase) Inhibitor Image Figure 2. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 4. Lynparza Image Figure 5. Zejula Image Figure 6. Rubraca Image Figure 7. Talzenna Image Figure 8. Other Image Figure 9. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 11. Ovarian Cancer Image Figure 12. Breast Cancer Image Figure 13. Other Image Figure 14. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2021-2032) & (US$ Million) Figure 16. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2021-2032) Figure 19. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (2021-2032) & (k units) Figure 20. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 21. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales YoY (2021-2032) & (k units) Figure 23. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales YoY (2021-2032) & (k units) Figure 24. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales YoY (2021-2032) & (k units) Figure 25. Asia (Excluding China) PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales YoY (2021-2032) & (k units) Figure 26. South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales YoY (2021-2032) & (k units) Figure 27. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2021-2032) Figure 33. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 34. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2021-2032) Figure 36. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2021-2032) Figure 39. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 40. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2021-2032) Figure 42. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Type (2021-2032) Figure 43. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Type (2021-2032) Figure 44. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Application (2021-2032) Figure 45. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Application (2021-2032) Figure 46. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country (2021-2032) Figure 47. North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Country (2021-2032) Figure 48. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Type (2021-2032) Figure 49. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Type (2021-2032) Figure 50. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Application (2021-2032) Figure 51. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Application (2021-2032) Figure 52. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country (2021-2032) Figure 53. Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Country (2021-2032) Figure 54. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Type (2021-2032) Figure 55. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Type (2021-2032) Figure 56. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Application (2021-2032) Figure 57. China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Application (2021-2032) Figure 58. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Type (2021-2032) Figure 59. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Type (2021-2032) Figure 60. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Application (2021-2032) Figure 61. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Application (2021-2032) Figure 62. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country (2021-2032) Figure 63. Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Country (2021-2032) Figure 64. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Type (2021-2032) Figure 65. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Type (2021-2032) Figure 66. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Application (2021-2032) Figure 67. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Application (2021-2032) Figure 68. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country (2021-2032) Figure 69. SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Country (2021-2032) Figure 70. PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain Figure 71. Manufacturing Cost Structure Figure 72. PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Lynparza
  • Zejula
  • Rubraca
  • Talzenna
  • Other
Applications
  • Ovarian Cancer
  • Breast Cancer
  • Other
Companies covered
  • AstraZeneca
  • Tesaro
  • Merck & Co
  • Clovis Oncology
  • Pfizer
  • GSK
  • Zai Lab

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Type
  3. 1.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Lynparza
  5. 1.2.3 Zejula
  6. 1.2.4 Rubraca
  7. 1.2.5 Talzenna
  8. 1.2.6 Other
  9. 1.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Application
  10. 1.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Ovarian Cancer
  12. 1.3.3 Breast Cancer
  13. 1.3.4 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Dynamics
  1. 2.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends
  2. 2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Drivers
  3. 2.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Opportunities and Challenges
  4. 2.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region
  3. 3.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2021-2026)
  5. 3.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2027-2032)
  6. 3.2.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2021-2032)
  7. 3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region
  9. 3.4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2021-2026)
  11. 3.4.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2027-2032)
  12. 3.4.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers
  2. 4.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers
  6. 4.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers, Product Type & Application
  13. 4.7 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market CR5 and HHI
  16. 4.8.2 2025 PARP (Poly ADP-Ribose Polymerase) Inhibitor Tier 1, Tier 2, and Tier 3
5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Type
  1. 5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type
  2. 5.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2021-2032)
  5. 5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type
  6. 5.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2021-2032)
  9. 5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type
6 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Application
  1. 6.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application
  2. 6.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2021-2032)
  5. 6.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application
  6. 6.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2021-2032)
  9. 6.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application
7 Company Profiles
  1. 7.1 AstraZeneca
  2. 7.1.1 AstraZeneca Company Information
  3. 7.1.2 AstraZeneca Business Overview
  4. 7.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  6. 7.1.5 AstraZeneca Recent Developments
  7. 7.2 Tesaro
  8. 7.2.1 Tesaro Company Information
  9. 7.2.2 Tesaro Business Overview
  10. 7.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  12. 7.2.5 Tesaro Recent Developments
  13. 7.3 Merck & Co
  14. 7.3.1 Merck & Co Company Information
  15. 7.3.2 Merck & Co Business Overview
  16. 7.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  18. 7.3.5 Merck & Co Recent Developments
  19. 7.4 Clovis Oncology
  20. 7.4.1 Clovis Oncology Company Information
  21. 7.4.2 Clovis Oncology Business Overview
  22. 7.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  24. 7.4.5 Clovis Oncology Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 GSK
  32. 7.6.1 GSK Company Information
  33. 7.6.2 GSK Business Overview
  34. 7.6.3 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  36. 7.6.5 GSK Recent Developments
  37. 7.7 Zai Lab
  38. 7.7.1 Zai Lab Company Information
  39. 7.7.2 Zai Lab Business Overview
  40. 7.7.3 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
  42. 7.7.5 Zai Lab Recent Developments
8 North America
  1. 8.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Type
  2. 8.1.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021-2032)
  3. 8.1.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2032)
  4. 8.1.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2021-2032)
  5. 8.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Application
  6. 8.2.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021-2032)
  7. 8.2.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2032)
  8. 8.2.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2021-2032)
  9. 8.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
  10. 8.3.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Type
  2. 9.1.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021-2032)
  3. 9.1.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2032)
  4. 9.1.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2021-2032)
  5. 9.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Application
  6. 9.2.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021-2032)
  7. 9.2.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2032)
  8. 9.2.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2021-2032)
  9. 9.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
  10. 9.3.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Type
  2. 10.1.1 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021-2032)
  3. 10.1.2 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2032)
  4. 10.1.3 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2021-2032)
  5. 10.2 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Application
  6. 10.2.1 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021-2032)
  7. 10.2.2 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2032)
  8. 10.2.3 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Type
  2. 11.1.1 Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021-2032)
  3. 11.1.2 Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2032)
  4. 11.1.3 Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2021-2032)
  5. 11.2 Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Application
  6. 11.2.1 Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021-2032)
  7. 11.2.2 Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2032)
  8. 11.2.3 Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2021-2032)
  9. 11.3 Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
  10. 11.3.1 Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Type
  2. 12.1.1 SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2021-2032)
  4. 12.1.3 SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type (2021-2032)
  5. 12.2 SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Application
  6. 12.2.1 SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2021-2032)
  8. 12.2.3 SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Application (2021-2032)
  9. 12.3 SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Country
  10. 12.3.1 SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain Analysis
  2. 13.1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Mode & Process
  6. 13.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors
  9. 13.2.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst